2010 Autumn Conference
13 – 14 October, 2010 // Baltimore, Maryland, USA
Poster Awardees: |
||
| Randomization Strategies for Clustered Clinical Syndromes: Effects on Statistical Power B Lebowitz, Y Wang, N Duan, CF Reynolds III, NM Simon, S Zisook, MK Shear |
||
| Reconsidering the Criterion for Excluding Comorbid Substance Use Disorders from Clinical Trials for the Treatment of Depression L Davis |
||
| Methodological Challenges of Demonstrating Cognitive Improvements with Broad Spectrum Agents: A Novel Approach Y Geffen, M Davidson, M Hufford, RM Gendreau, S Rao, R.Zablocki, J Kranzler |
||
Day 1 (13 October 2010) |
||
| President’s Welcome | L Alphs slides video |
|
| S1: MATRICS Update and Beyond |
Chairs: S Marder M Egan |
|
| Introduction | S Marder slides video |
|
| The MATRICS Approach to Measuring Cognition: Foundational Issues and Critical Decisions | M Green slides |
|
| Real-World Application of the MATRICS Consensus Cognitive Battery (MCCB) in Multisite Clinical Trials | R Keefe slides video |
|
| Assessment of Functional Outcomes | D Velligan slides video |
|
| Challenges in Drug Development for Cognitive Impairment Associated with Schizophrenia | M Egan* |
|
| Cognition in Schizophrenia: New Directions in Clinical Trials at NIMH | B Cuthbert slides |
|
| Bridging the Gaps Between Animal Models, Human Neuroscience and Schizophrenia Clinical Trials: Rational Enhancement of Signal Detection | J Sweeney slides |
|
| Cognitive Remediation as a Platform for Clinical Trials of Cognitive Enhancing Drugs in Schizophrenia | A Reichenberg slides |
|
| Cognitive Assessment for Schizophrenia Clinical Trials in the Post-MATRICS Era | R Bilder slides |
|
| Standardized Approach to Clinical Trials: Risks, Benefits, and a Working Model | S Koslow slides |
|
| Exemplar Applications and Results From BRAINnet: What Are The Implications for Understanding, Modeling, Diagnosing and Treating Brain Disorders? | S Silverstein slides |
|
| Regulatory Perspective MATRICS and Beyond: US Perspective | T Laughren video |
|
| Regulatory Perspective MATRICS and Beyond: European Perspective | K Broich slides video |
|
| Panel Discussion | Chair: M Egan videoPanelists: K Broich T Laughren R Keefe video |
|
| Summary | S Marder video |
|
| Poster Session | View All Poster Abstracts | |
Day 2 (14 October 2010) |
||
| S2: Concurrent Workshops | ||
| Sources And Management Of Placebo Effects In CNS Clinical Trials | A Kalali L Ereshefsky slides (summary) |
|
| Methodological Issues for Studying Negative Symptoms of Schizophrenia | S Marder D Daniel video |
|
| Health Information Technology and Electronic Medical Records: What Are the Scientific and Policy Priorities for the Field of CNS Clinical Research? | J Davis R Ferziger |
|
| Questionable Data: Recognition and Resolution | G Sachs J Severe slides (Colton) slides (summary) video |
|
| Mitochondrial Systems as Targets for Development of Novel Pharmacological Interventions for CNS Disorders Session Summary |
C Bowden A Nierenberg slides (summary) |
|
| Suicidality Assessment in Clinical Trials: Methodological and Technical Challenges | A Butler M Stewart slide (Mathis) slides (summary) |
|
| Session 3: DSM-5: Implications for Clinical Trials | Chairs: N Schooler R Hirschfeld |
|
| Introduction | N Schooler video |
|
| Implications of DSM-5 Mood Disorders for Future Treatment Efficacy Trials | J Fawcett slides video |
|
| Schizophrenia and Psychotic Disorders in DSM-5 | J Bustillo slides |
|
| Regulatory Perspectives from FDA and EMEA | M Mathis slides K Broich slides |
|
| Public Perspective | J McNulty video |
|
| General Discussion | R Hirschfeld | |
| Meeting Adjourns | ||
| * Materials have not been released. | ||